Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | JNJ-78278343 |
Trade Name | |
Synonyms | JNJ78278343|JNJ 78278343 |
Drug Descriptions |
JNJ-78278343 is a humanized IgG1 bispecific antibody that targets KLK2 on tumor cells and CD3 on T lymphocytes, which may lead to T-lymphocyte activation and cell killing of tumor cells expressing KLK2 (NCI Drug Dictionary). |
DrugClasses | CD3 Antibody 97 |
CAS Registry Number | NA |
NCIT ID | C180825 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cetrelimab + JNJ-78278343 | Cetrelimab JNJ-78278343 | 0 | 1 |
JNJ-78278343 | JNJ-78278343 | 0 | 1 |
JNJ-78278343 + JNJ-87189401 | JNJ-78278343 JNJ-87189401 | 0 | 1 |